Consensus on molecular imaging and theranostics in prostate cancer

Fanti, Stefano; Minozzi, Silvia; Antoch, Gerald; Banks, Ian; Briganti, Alberto; Carrió, Ignasi; Chiti, Arturo; Clarke, Noel W.; Eiber, Matthias; Bono, Johann S. de; Fizazi, Karim; Gillessen, Silke; Gledhill, Sam; Haberkorn, Uwe; Herrmann, Ken; Hicks, Rodney J.; Lecouvet, Frédéric; Montironi, Rodolfo; Ost, Piet; O’Sullivan, Joe M.; Padhani, Anwar R.; Schalken, Jack A.; Scher, Howard I.; Tombal, Bertrand; Moorselaar, R. Jeroen A. van; Poppel, H. Van; Vargas, Hebert Alberto; Walz, Jochen; Weber, Wolfgang; Wester, Hans‐Jürgen; Oyen, Wim J.G.

doi:10.1016/s1470-2045(18)30604-1

Cited by 97 publications

(72 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PSMA‐PET has excellent sensitivity and specificity and is a superior modality for detecting PCa lesions compared to choline‐based PET imaging . Based on the responses of a multidisciplinary panel of international experts, PSMA‐PET has become the preferred modality for staging biochemically recurrent and advanced PCa . With PSMA‐PET, the risk of untreated occult metastatic PCa lesions is lowered.…”

Section: Discussionmentioning

confidence: 99%

“…15 Based on the responses of a multidisciplinary panel of international experts, PSMA-PET has become the preferred modality for staging biochemically recurrent and advanced PCa. 16 With PSMA-PET, the risk of untreated occult metastatic PCa lesions is lowered. This could explain the slightly higher TE-FS in our study compared to ADT-FS in previous studies, even though we adopted a broad definition of treatment escalation and included patients with up to five initial lesions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial

Bowden¹,

See²,

Frydenberg

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Stereotactic body radiotherapy (SBRT) can delay escalation to systemic treatment in men with oligometastatic prostate cancer (PCa). However, large, prospective studies are still required to evaluate the efficacy of this approach in different patient groups. This is the interim analysis of a prospective, single institution study of men relapsing with up to five synchronous lesions following definitive local treatment for primary PCa. Our aim was to determine the proportion of patients not requiring treatment escalation following SBRT. In total, 199 patients were enrolled to receive fractionated SBRT (50 Gray in 10 fractions) to each visible lesion. Fourteen patients were castration resistant at enrolment. The proportion of patients not requiring treatment escalation 2 years following SBRT was 51.7% (95% CI: 44.1–59.3%). The median length of treatment escalation‐free survival over the entire follow‐up period was 27.1 months (95% CI; 21.8–29.4 months). Prior androgen deprivation therapy (ADT) predicted a significantly lower rate of freedom from treatment escalation at 2 years compared to no prior ADT (odds ratio = 0.21, 95% CI: 0.08–0.54, p = 0.001). There was no difference in the efficacy of SBRT when treating 4–5 vs. 1–3 initial lesions. A prostate‐specific antigen (PSA) decline was induced in 75% of patients, with PSA readings falling to an undetectable level in six patients. No late grade three toxicities were observed. These interim results suggest that SBRT can be used to treat up to five synchronous PCa oligometastases to delay treatment escalation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial

Bowden¹,

See²,

Frydenberg

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Available data report a slight superiority over choline, 2,3 but it is likely that PSMA ligands outperform fluciclovine in biochemical relapse. 3 Radiolabelled PSMA ligands (Ga-68 and F-18) -of all available prostate cancer PET agents, PSMA ligands represent the biggest advance. [3][4][5][6][7][8] These are receptor agents (rather than metabolic markers) that bind to a surface transmembrane glycoprotein.…”

Section: F-18 Labelled Fluciclovine (Axumin)mentioning

confidence: 99%

PSMA PET ligands in prostate cancer: a game‐changer?

Dhawan

Barwick

Khan

et al. 2019

Trends Urol & Men's Health

View full text Add to dashboard Cite

show abstract

“…If the answer to any of these questions is no, then it is very unlikely that the tracer will ‘cross the line’ and receive approval. The ‘Consensus on molecular imaging and theranostics in prostate cancer’ published in Lancet Oncology this December is clear proof of this . Despite the massive number of papers published in the last few years on radiolabelled prostate‐specific membrane antigen (PSMA), the outcome of the aforementioned ‘Consensus’ appears to be that a definitive consensus cannot be reached .…”

mentioning

confidence: 99%

“…The ‘Consensus on molecular imaging and theranostics in prostate cancer’ published in Lancet Oncology this December is clear proof of this . Despite the massive number of papers published in the last few years on radiolabelled prostate‐specific membrane antigen (PSMA), the outcome of the aforementioned ‘Consensus’ appears to be that a definitive consensus cannot be reached . In the frenetic worldwide rush to implement new drugs , it is a relief that we still have the solid anchor of evidence‐based medicine requirements that are strictly applied even to the ‘coolest’ radiopharmaceutical of recent years in prostate cancer imaging and therapy.…”

mentioning

confidence: 99%